The extension of Cure Pharmaceutical Holding Corp (OTCMKTS:CURR) license will enable it to continue working on its psychedelics program to advance it further. The vertically integrated drug delivery and product development business wants to achieve a lot in line with its research advancement and expand its specialty pharmaceutical pipeline.
The Schedule I U.S. Drug Enforcement Agency (DEA) license
It is pretty pleased after securing an extension to its Schedule I U.S. Drug Enforcement Agency (DEA) license and vows to take advantage of the psychedelics-based pharmaceuticals research to come up with safe and trusted products. Reports indicate that the company will use various compounds to find top solutions for handling mental health disorders. Some of the compounds the company intends to use are MDMA, LSD, and psilocybin.
Any company that wants to obtain the Schedule I license must be good at handling some wide-ranging drug substances. The regulations provide that the company in question must prove its prowess in handling drugs with great abuse potential and those that still haven’t been accepted for medical use.
Obtaining such a license could be one of the most grueling undertakings for any company, and that is because the party in question has to move through a very rigorous exercise. For example, the company needs to present an elaborate scientific investigation in a formal application. The other requirements would be proof of confirmation of the facility’s security and the inspection of laboratory facilities.
CURE makes a step in the right direction with the latest license, relying on its facilities in conducting fully integrated research. The company’s patented delivery platform and the excellent choice of top compounds are significant steps forward. The reliance on innovative solutions depicts a company committed to generating a significant impact on the unmet patient need segments.
Davidson speaks out on the matter
The company’s CEO Rob Davidson is quite pleased after the company managed to get the license. This official says that he will lead the company towards achieving a lot from expanding the specialty pharmaceutical pipeline.
He reveals that the company will focus its resources and efforts towards research advancement and that everything will be conducted legally and safely. Davidson outlines that they have always been the sort of company that focuses on providing some outstanding patient solutions. He vows to uphold the same spirit as the focus on utilizing the expanded license.